NASDAQ:IRMD - Iradimed Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$29.35 +0.05 (+0.17 %)
(As of 08/21/2018 11:55 AM ET)
Previous Close$29.25
Today's Range$29.05 - $29.45
52-Week Range$9.25 - $30.60
Volume1,211 shs
Average Volume109,722 shs
Market Capitalization$314.53 million
P/E Ratio365.00
Dividend YieldN/A
Beta1.42
Iradimed logoIRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022

Debt

Debt-to-Equity RatioN/A
Current Ratio8.36
Quick Ratio7.40

Price-To-Earnings

Trailing P/E Ratio365.00
Forward P/E Ratio79.32
P/E GrowthN/A

Sales & Book Value

Annual Sales$23.08 million
Price / Sales13.58
Cash Flow$0.2147 per share
Price / Cash136.70
Book Value$3.12 per share
Price / Book9.41

Profitability

EPS (Most Recent Fiscal Year)$0.08
Net Income$490,000.00
Net Margins9.57%
Return on Equity8.99%
Return on Assets7.61%

Miscellaneous

Employees83
Outstanding Shares10,680,000
Market Cap$314.53 million

Iradimed (NASDAQ:IRMD) Frequently Asked Questions

What is Iradimed's stock symbol?

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

How will Iradimed's stock buyback program work?

Iradimed declared that its Board of Directors has initiated a stock buyback plan on Sunday, June 4th 2017, which allows the company to buyback $8,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

How were Iradimed's earnings last quarter?

Iradimed Corp (NASDAQ:IRMD) announced its earnings results on Tuesday, July, 31st. The medical equipment provider reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The medical equipment provider had revenue of $7.38 million for the quarter, compared to the consensus estimate of $7.26 million. Iradimed had a return on equity of 8.99% and a net margin of 9.57%. View Iradimed's Earnings History.

When is Iradimed's next earnings date?

Iradimed is scheduled to release their next quarterly earnings announcement on Monday, October, 29th 2018. View Earnings Estimates for Iradimed.

What price target have analysts set for IRMD?

2 brokers have issued 12-month price objectives for Iradimed's stock. Their forecasts range from $19.00 to $26.00. On average, they anticipate Iradimed's stock price to reach $22.50 in the next twelve months. This suggests that the stock has a possible downside of 23.3%. View Analyst Price Targets for Iradimed.

What is the consensus analysts' recommendation for Iradimed?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.

Who are some of Iradimed's key competitors?

Who are Iradimed's key executives?

Iradimed's management team includes the folowing people:
  • Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 65)
  • Mr. Christopher K. Scott, CFO & Sec. (Age 48)
  • Mr. John McCreery, Chief Operating Officer (Age 63)
  • Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 59)
  • Mr. Louis Waldman, Controller (Age 63)

Has Iradimed been receiving favorable news coverage?

News stories about IRMD stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a media and rumor sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 48.99 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Iradimed.

Who are Iradimed's major shareholders?

Iradimed's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.15%), Mondrian Investment Partners LTD (1.58%), Cadence Capital Management LLC (1.35%), Renaissance Technologies LLC (1.10%), Russell Investments Group Ltd. (0.83%) and Boston Partners (0.59%). Company insiders that own Iradimed stock include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

Which institutional investors are selling Iradimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including Mondrian Investment Partners LTD and Boston Partners. Company insiders that have sold Iradimed company stock in the last year include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.

Which institutional investors are buying Iradimed stock?

IRMD stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Cadence Capital Management LLC, Russell Investments Group Ltd., Bank of America Corp DE, EAM Investors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Iradimed.

How do I buy shares of Iradimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iradimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $29.35.

How big of a company is Iradimed?

Iradimed has a market capitalization of $314.53 million and generates $23.08 million in revenue each year. The medical equipment provider earns $490,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Iradimed employs 83 workers across the globe.

How can I contact Iradimed?

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]


MarketBeat Community Rating for Iradimed (NASDAQ IRMD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel